USP1 and neoplasm: The development of a first in class USP1 inhibitor, i.e., KSQ-4279, capable to inhibit tumor growth in models partially sensitive to PARP inhibitors and to induce durable tumor regression in combination with PARP inhibitors is ongoing 119.